Skip to content
Research Article Open access CC BY 4.0

Characteristics of D-Dimer Levels in Patients Confirmed Positive for COVID-19 Aged 45 – 70 Years at UKI Hospital for the Period December 2020 – September 2021

Danny Ernest Jonas Luhulima, Welly Saluntondok, Nafisah Erica Maulidiani Irwan

Journal of Complementary and Alternative Medical Research · pp. 40–52 · Published 29 Jan 2024

10.9734/jocamr/2024/v25i1513

Abstract

COVID-19 is a disease caused by the SARS-CoV-2 virus. COVID-19 is divided into several clinical symptoms based on a person's experiences. In severe clinical signs of COVID-19, D –Dimer will be significantly higher. This study aims to determine D-Dimer levels in COVID-19 patients aged 45 – 70 and uses a descriptive-analytic method with a retrospective cross-sectional design. The number of samples was 198 patients whose D-Dimer levels were checked and 127 patients who received anticoagulant prophylaxis. The research samples were all medical records of patients suffering from COVID-19 aged 45 - 70 years and who had checked D-Dimer levels at RSU UKI from December 2020 to September 2021 found that 145 patients (73.2%) had normal D-Dimer levels, 53 patients (26.8%) had increased D-Dimer levels. The distribution of women were 100 patients (50.5%), and men were 98 patients (49.5%), the highest range was aged 54 - 62 years with 74 patients (37.4%), clinical symptoms were being experienced by 122 patients (61.6%), and comorbid hypertension was the most common disease with 64 patients (32.3%). A significant relationship was found between D-Dimer levels and comorbidities (p=0.04). Anticoagulant prophylaxis was given to 127 patients, with mild symptoms experienced by five patients (3.6%), moderate symptoms experienced by 73 patients (57.5%), and severe symptoms experienced by 49 patients (38.6%). However, no significant relationship was found (p=0.66) between administering anticoagulant prophylaxis and D-Dimer levels in patients with mild, moderate, or severe symptoms.

D-dimer age covid-19 anticoagulants

References (33)

  1. 1 COVID-19 pathophysiology: A review [DOI]
  2. 2 Molecular immune pathogenesis and diagnosis of COVID-19 [DOI]
  3. 3 Return of the Coronavirus: 2019-nCoV [DOI]
  4. 4 Coronavirus disease 2019 (COVID-19): current status and future perspectives [DOI]
  5. 5 COVID-19: Transmission, prevention, and potential therapeutic opportunities [DOI]
  6. 6 D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study [DOI]
  7. 7 Human Vaccines & Immunotherapeutics [DOI]
  8. 8 Role of Mass Media and Public Health Communications in the COVID-19 Pandemic [DOI]
  9. 9 D-dimer level in COVID-19 infection: a systematic review [DOI]
  10. 10 D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19 [DOI]
  11. 11 The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status [DOI]
  12. 12 Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19 [DOI]
  13. 13 The Pathogenesis of Coronavirus Disease 2019 (COVID‐19): Evaluation and Prevention [DOI]
  14. 14 Pulmonary Thrombosis and Thromboembolism in COVID-19 [DOI]
  15. 15 Porcine Deltacoronavirus Engages the Transmissible Gastroenteritis Virus Functional Receptor Porcine Aminopeptidase N for Infectious Cellular Entry [DOI]
  16. 16 Coronavirus Disease 2019 (COVID-19): Patogenesis, Manifestasi Klinis dan Pilihan Terapi [DOI]
  17. 17 Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine [DOI]
  18. 18 Anticoagulation in COVID-19: current concepts and controversies [DOI]
  19. 19 Serum D-dimer levels at admission for prediction of outcomes in acute pancreatitis [DOI]
  20. 20 Coronavirus disease (COVID-19) [DOI]
  21. 21 The Clinical Laboratory: A Key Player in Diagnosis and Management of COVID-19.
  22. 22 Karakteristik Pasien COVID-19 Rawat Inap di RS Immanuel Bandung, Indonesia [DOI]
  23. 23 Coronavirus disease 2019—Historical context, virology, pathogenesis, immunotherapy, and vaccine development [DOI]
  24. 24 Hemostasis dan Disseminated Intravascular Coagulation (DIC) [DOI]
  25. 25 D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review
  26. 26 HEMOSTASIS BERLANDASKAN SEL HIDUP (IN VIVO) [DOI]
  27. 27 Penggunaan Heparin Dosis Tinggi pada Pasien COVID-19 dengan ARDS dan Hipertensi di Unit Perawatan Intensif (ICU) [DOI]
  28. 28 GAMBARAN PENGGUNAAN ANTIKOAGULAN PADA PASIEN COVID-19 DI SALAH SATU RUMAH SAKIT RUJUKAN COVID-19 DI KOTA SEMARANG [DOI]
  29. 29 Arteriosclerosis, Thrombosis, and Vascular Biology [DOI]
  30. 30 Journal of Infection and Chemotherapy [DOI]
  31. 31 Indonesian Journal of Clinical Pathology and Medical Laboratory [DOI]
  32. 32 Is a 14-day quarantine period optimal for effectively controlling coronavirus disease 2019 (COVID-19)? [DOI]
  33. 33 PNEUMONIA : EPIDEMIOLOGI, FAKTOR RISIKO PADA BALITA [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

67

Page views

0

PDF downloads

15

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.